Randomized phase II trial of cixutumumab alone or with cetuximab for refractory recurrent/metastatic head and neck squamous cell carcinoma

Cetuximab, a human-murine monoclonal antibody targeting the epidermal growth factor receptor (EGFR), is the only targeted therapy that has shown meaningful clinical activity and is approved for the treatment of head and neck squamous cell carcinoma (HNSCC). In the recurrent/metastatic (R/M) setting, it can be used in first line combined with platinum and 5-fluorouracil, or as single agent after progression on first line platinum-based chemotherapy, leading to an overall response rate (ORR) of 13% and disease control rate of 46% [1].

Source: Oral Oncology - May 19, 2018 Category: Cancer & Oncology Authors: Renata Ferrarotto, William N. William, Jennifer E. Tseng, Shanthi Marur, Dong M. Shin, Barbara Murphy, Ezra E.W. Cohen, Christopher Y. Thomas, Richard Willey, Jan Cosaert, Nusrat Harun, J. Jack Lee, Ignacio W. Wistuba, Robert I. Haddad, Bonnie S. Glisson Source Type: research